We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 17 for:    Multi-cancer early detection test

Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial (NHS-Galleri)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05611632
Recruitment Status : Active, not recruiting
First Posted : November 10, 2022
Last Update Posted : November 10, 2022
Sponsor:
Collaborator:
Cancer Research UK and King's College London Cancer Prevention Trials Unit (UK)
Information provided by (Responsible Party):
GRAIL, LLC

Brief Summary:

The Galleri test is a new test that looks for potential signs of cancer in a blood sample. The test can find many different types of cancer but cannot find all cancers. The trial aims to see if using the Galleri test alongside standard cancer testing in the NHS can help to find cancers at an early stage when they are easier to treat.

The trial has enrolled approximately 140,000 participants who will be actively followed for approximately three years from the date of enrollment.


Condition or disease Intervention/treatment Phase
Cancer Device: Multi-cancer early detection test (Galleri test) Not Applicable

Detailed Description:

This is a prospective, randomized, controlled trial to assess the performance and clinical utility of a multi-cancer early detection test for population screening in the UK when added to standard of care. Participants and the study teams remain blinded throughout the study with the exception of the study nurses returning the results and a small number of staff to enable them to perform administrative duties. Blinding is maintained for participants with the exception of those participants who test positive. Those who test positive will be informed by designated trial staff and will be referred for standard of care investigations and treatment. Trial sponsor employees, the CIs and site staff (unless identified differently in the blinding plan for study conduct needs) will remain blinded throughout the study.

Randomization will be to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.

Unless diagnosed with cancer, participants in both arms will be asked to return for annual visits at approximately 12 and 24 months. All participants whether test positive, test negative or not tested will be followed for cancer and associated outcomes via NHS dataset linkages.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomised to either the intervention arm, with blood collection and evaluation of the test with consequent investigation and treatment of a positive test through referral to the NHS urgent two week wait pathway, or to the control arm, where blood samples are collected at designated intervals and will be stored for potential future evaluation, but participants do not receive test results and otherwise continue to receive routine NHS care.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Screening
Official Title: A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
Actual Study Start Date : August 31, 2021
Estimated Primary Completion Date : July 15, 2024
Estimated Study Completion Date : February 28, 2026

Arm Intervention/treatment
Experimental: Interventional
Blood collection and multi-cancer early detection testing with return of positive test results.
Device: Multi-cancer early detection test (Galleri test)
Blood collection and multi cancer early detection testing with return of positive test results.
Other Name: Galleri test

No Intervention: Control
Blood collection only.



Primary Outcome Measures :
  1. absolute numbers of stage III and IV cancers diagnosed [ Time Frame: 3-4 years after randomization ]

Secondary Outcome Measures :
  1. absolute numbers of advanced cancers (stage III and IV cancers or one that results in a cancer-specific death) diagnosed [ Time Frame: 3-4 years after randomization ]
  2. absolute numbers of stage IV cancers diagnosed [ Time Frame: 1 years after randomization ]
  3. absolute numbers of stage IV cancers diagnosed [ Time Frame: 3-4 years after randomization ]
  4. cancer-specific mortality for a pre-specified group of cancer types [ Time Frame: 3-4 years after randomization ]
  5. cancer-specific mortality [ Time Frame: up to 8 years after randomization ]
  6. proportion of Stage I and II cancers [ Time Frame: 3-4 years after randomization ]
  7. test performance (sensitivity, specificity, positive predictive value, negative predictive value) and cancer signal origin accuracy) in the intervention arm. [ Time Frame: Up to 3 years ]
  8. number of follow up procedures and invasive procedures, complications and deaths associated with follow-up diagnostic procedures in all test positive cases [ Time Frame: Up to 3 years ]
  9. number and type of invasive procedures performed in false positive cases [ Time Frame: Up to 3 years ]
  10. radiation exposure measured in mSv per participant due to test result directed evaluations in all test positive cases [ Time Frame: Up to 3 years ]
  11. psychological impact using the short form State Trait Anxiety Index-6 questionnaire (a six item validated measure of state anxiety), at various timepoints in all test positive cases [ Time Frame: Up to 3 years ]
    Scores range from 20-80 with the general population expected to score 34-36 and very high anxiety classed as scoring > 49.


Other Outcome Measures:
  1. healthcare resource utilisation [ Time Frame: Up to 3 years ]
    The data collected may be used to conduct future exploratory economic analyses, and will include: Number and types of medical encounters and cancer-specific diagnostic and treatment procedures, including clinical lab visits, imaging tests, invasive tests, and clinic visits.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 77 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Participants must be at 50-77 years of age, inclusive, at the time of data extraction from NHS datasets or GP records used to identify potential participants; and
  2. Capable of giving signed and legally effective informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Consent provided by a legally authorised representative is not permitted in this protocol.

Exclusion Criteria:

  1. Previous or current participation in another GRAIL-sponsored study.
  2. Personal history of invasive cancer or haematologic malignancy, diagnosed within the three years prior to expected enrolment date. Note: Individuals with a diagnosis of non-melanoma skin cancer and prostate cancer patients whose only treatment is active surveillance are NOT excluded
  3. Definitive treatment for invasive cancer or haematologic malignancy within the 3 years prior to expected enrolment date, including adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer).
  4. Currently taking demethylating or cytotoxic agents for any condition.
  5. Undergoing current investigation for suspected cancer, defined as having been referred to a two week wait clinic or undergoing investigations at an RDC or other clinic with a stated suspicion of cancer.
  6. Currently on a palliative care pathway.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05611632


Locations
Layout table for location information
United Kingdom
EMS Healthcare Ltd
Chester, United Kingdom
Sponsors and Collaborators
GRAIL, LLC
Cancer Research UK and King's College London Cancer Prevention Trials Unit (UK)
Investigators
Layout table for investigator information
Study Director: Liz Holmes GRAIL, LLC
Layout table for additonal information
Responsible Party: GRAIL, LLC
ClinicalTrials.gov Identifier: NCT05611632    
Other Study ID Numbers: GRAIL-009
ISRCTN91431511 ( Registry Identifier: ISRCTN )
First Posted: November 10, 2022    Key Record Dates
Last Update Posted: November 10, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by GRAIL, LLC:
multi-cancer early detection
cancer screening
MCED
circulating cell-free tumor DNA